Safety and Efficacy of Long-term Somatropin Treatment in Adults

Novo Nordisk A/S752 enrolled

Overview

This study is conducted in Europe. The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).

Study Type

OBSERVATIONAL

Enrollment

752

Prescribed at the discretion of the treating physician according to product labelling

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * In need of somatropin or current user

Unnamed facility

Mainz, Germany

Number of adverse events

Time frame: Up to 10 years

BMI (Body Mass Index)

Time frame: Up to 10 years

HbA1c change

Time frame: Up to 10 years

IGF-I (Insulin-Like Growth Factor I)

Time frame: Up to 10 years

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.